tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Meningitis, Fungal D016921 1 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Dysuria D053159 1 associated lipids
Denys-Drash Syndrome D030321 1 associated lipids
Akinetic Mutism D000405 1 associated lipids
Sleep Apnea, Central D020182 1 associated lipids
Orchitis D009920 1 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Schwartz JJ et al. Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression. 2007 Transplantation pmid:17893604
Yamagami S et al. Mechanism of concordant corneal xenograft rejection in mice: synergistic effects of anti-leukocyte function-associated antigen-1 monoclonal antibody and FK506. 1997 Transplantation pmid:9233699
Singh N et al. Immunosuppressive-associated leukoencephalopathy in organ transplant recipients. 2000 Transplantation pmid:10708096
Boyer O et al. Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. 2005 Transplantation pmid:15912111
Gonwa T et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. 2003 Transplantation pmid:12717205
Neuhaus P et al. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. 1995 Transplantation pmid:7530868
Tzakis AG et al. Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation. 2003 Transplantation pmid:12717207
Numakura K et al. Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. 2005 Transplantation pmid:16340785
Ashokkumar C et al. Allospecific CD154+ T-cytotoxic memory cells identify recipients experiencing acute cellular rejection after renal transplantation. 2011 Transplantation pmid:21747326
Stegall MD et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. 1997 Transplantation pmid:9422416
Takeguchi N et al. Inhibition of the multidrug efflux pump in isolated hepatocyte couplets by immunosuppressants FK506 and cyclosporine. 1993 Transplantation pmid:7681229
Bundick RV et al. FK506 as an agonist to induce inhibition of interleukin 2 production. 1992 Transplantation pmid:1374947
Casey MJ et al. Prolonged immunosuppression preserves nonsensitization status after kidney transplant failure. 2014 Transplantation pmid:24717218
Kasahara M et al. Living-related liver transplantation for type II citrullinemia using a graft from heterozygote donor. 2001 Transplantation pmid:11211185
Ovuworie CA et al. Vascular endothelial function in cyclosporine and tacrolimus treated renal transplant recipients. 2001 Transplantation pmid:11685108
Mourad G et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. 2001 Transplantation pmid:11579299
Xue F et al. Immune cell functional assay in monitoring of adult liver transplantation recipients with infection. 2010 Transplantation pmid:20010326
Manitpisitkul W et al. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: a case-control study. 2009 Transplantation pmid:19584685
Esquivel CO et al. Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients. 1996 Transplantation pmid:8607198
Jiang H et al. Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. 2002 Transplantation pmid:12085006
Shapiro R et al. Posttransplant diabetes in pediatric recipients on tacrolimus. 1999 Transplantation pmid:10096540
David-Neto E et al. Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation. 2017 Transplantation pmid:27482958
Merkle M et al. The effect of sevelamer on tacrolimus target levels. 2005 Transplantation pmid:16177649
Cooper MH et al. Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors. 1994 Transplantation pmid:7509089
Lo A et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. 2004 Transplantation pmid:15114090
Shoker A et al. Heightened CD40 ligand gene expression in peripheral CD4+ T cells from patients with kidney allograft rejection. 2000 Transplantation pmid:10949194
Vivarelli M et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. 2010 Transplantation pmid:20098287
Jacobson PA et al. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium. 2012 Transplantation pmid:22334041
Schneeberger S et al. Cytomegalovirus-related complications in human hand transplantation. 2005 Transplantation pmid:16123716
Borger P et al. Cyclosporine, FK506, mycophenolate mofetil, and prednisolone differentially modulate cytokine gene expression in human airway-derived epithelial cells. 2000 Transplantation pmid:10798763
Ceulemans LJ et al. Nonsteroidal anti-inflammatory drug-induced intestinal graft loss 12 years after transplantation. 2015 Transplantation pmid:25695790
Macedo C et al. Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. 2012 Transplantation pmid:22343334
Kasahara M et al. Role of HLA compatibility in pediatric living-related liver transplantation. 2002 Transplantation pmid:12438966
Nakajima K et al. Prolongation of cardiac xenograft survival in rats treated with 15-deoxyspergualin alone and in combination with FK506. 1988 Transplantation pmid:2454521
Chan L et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. 2008 Transplantation pmid:18360262
Saad ER et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. 2008 Transplantation pmid:18360267
Maluccio M et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. 2003 Transplantation pmid:12923450
Ryu S and Yasunami Y The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. 1991 Transplantation pmid:1718064
Mendez R et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. 2005 Transplantation pmid:16082323
Wang HD et al. Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation. 2018 Transplantation pmid:29298238
Starzl TE et al. Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and rapamycin. 1991 Transplantation pmid:1718068
Risaliti A et al. Cardiovascular and metabolic complications after liver transplantation: Neoral- versus tacrolimus-based immunosuppression. 2001 Nov-Dec Transplant. Proc. pmid:11750569
Vanrenterghem Y et al. Co-administration of tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. 1998 Transplant. Proc. pmid:9636523
Riveiro-Barciela M et al. Hyperkalemic distal renal tubular acidosis caused by immunosuppressant treatment with tacrolimus in a liver transplant patient: case report. 2011 Transplant. Proc. pmid:22172892
Marin-Gomez LM et al. Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study. 2009 Jul-Aug Transplant. Proc. pmid:19715867
Bruce DS et al. Effects of tacrolimus, mycophenolate mofetil, and cyclosporine microemulsion on rejection incidence in synchronous pancreas-kidney transplantation. 1998 Transplant. Proc. pmid:9532150
Tang J et al. Cytokine Profile in Calcineurin Inhibitor-Induced Chronic Nephrotoxicity in Chinese Liver Transplant Recipients. 2016 Transplant. Proc. pmid:27788813
Ortiz de Urbina J et al. Advagraf de novo in liver transplantation: a single-center experience. 2011 Transplant. Proc. pmid:21486583
Staschak S et al. A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent. 1990 Transplant. Proc. pmid:1689896
Tanabe M et al. The influence of donor and recipient strains in isolated small bowel transplantation in rats. 1994 Transplant. Proc. pmid:7527986
Tabasco-Minguillan J et al. Long-term insulin requirement after liver transplantation with FK 506 in American veterans. 1993 Transplant. Proc. pmid:7679839
Abu-Elmagd KM et al. Strategy of FK 506 therapy in liver transplant patients: effect of graft function. 1991 Transplant. Proc. pmid:1721272
Kusne S et al. Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation. 1992 Transplant. Proc. pmid:1371626
Tanaka M et al. Tacrolimus (FK 506)-dependent tolerance after liver and heart xenotransplantation: inhibition of humoral response and acceptance of donor organs. 1996 Transplant. Proc. pmid:8623341
Mueller AR et al. Does initial graft function influence the outcome after liver transplantation? 1998 Transplant. Proc. pmid:9636594
Takeuchi H et al. Lymphocyte sensitivity to cyclosporine and tacrolimus in chronic renal failure patients and clinical significance in renal transplantation. 1998 Transplant. Proc. pmid:9474950
Akiyama T et al. Mizoribine in combination therapy with tacrolimus for living donor renal transplantation: analysis of a nationwide study in Japan. 2005 Transplant. Proc. pmid:15848551
Moffatt SD and Metcalfe SM FK 506 versus cyclosporine in combination with anti-CD4/CD8 monoclonal antibodies. 1999 Transplant. Proc. pmid:10578271
Connelly PR Thermodynamics of interaction of FK 506-binding protein and its ligands. 1991 Transplant. Proc. pmid:1721304
Petan JA et al. Physiochemical properties of generic formulations of tacrolimus in Mexico. 2008 Transplant. Proc. pmid:18589125
Bäckman L et al. Chronic nephrotoxicity of FK 506 after liver transplantation. 1994 Transplant. Proc. pmid:7518159
Sakai K et al. The pathologic impact of tacrolimus on protocol biopsy in renal transplant patients with basiliximab-based immunosuppression. 2005 Transplant. Proc. pmid:15919455
Sakimoto H et al. Prolonged survival of hamster-to-rat pancreas xenografts by FK 506 and splenectomy. 1995 Transplant. Proc. pmid:7533394
Gaston RS Potential utility of rapamycin and tacrolimus in long-term, low-toxicity regimens. 1999 Transplant. Proc. pmid:10616556
Braun F et al. Therapeutic drug monitoring of tacrolimus early after liver transplantation. 2002 Transplant. Proc. pmid:12176473
Schorlemmer HU et al. Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus. 1998 Transplant. Proc. pmid:9865312
Moro JA et al. Randomized prospective study of the evolution of renal function depending on the anticalcineurin used. 2008 Transplant. Proc. pmid:19010143
Walgenbach KJ et al. Increased presence of mast cells and interleukin-4 during chronic rejection of rat intestinal allografts. 1996 Transplant. Proc. pmid:8907896
Gordon RD et al. Liver transplantation under cyclosporine: a decade of experience. 1991 Transplant. Proc. pmid:1703339
Rosh JR et al. Therapy with FK 506 in pediatric liver recipients. 1994 Transplant. Proc. pmid:7509091
Souza ER et al. Acute effects of FK 506 on glomerular hemodynamics. 1992 Transplant. Proc. pmid:1281585
Darras FS et al. Transplantation of pediatric en bloc kidneys under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721368
Nishi K et al. The colon displays an absorptive capacity of tacrolimus. 2004 Transplant. Proc. pmid:15050160
Hernández D et al. Cardiovascular risk profile in nondiabetic renal transplant patients: cyclosporine versus tacrolimus. 2003 Transplant. Proc. pmid:12962773
Chien YS et al. Incidence and risk factors of new-onset diabetes mellitus after renal transplantation. 2008 Transplant. Proc. pmid:18790250
Tsuchimoto S et al. Orthotopic liver transplantation in rats receiving FK506. 1989 Transplant. Proc. pmid:2468208
Ito A et al. Induction of tolerance in rat cardiac allograft model by intrathymic injection of donor bone marrow cells. 1995 Transplant. Proc. pmid:7536974
DiMartini A et al. Psychiatric morbidity in liver transplant patients. 1991 Transplant. Proc. pmid:1721399
Moutabarrik A et al. Effect of FK 506 and cyclosporine on the expression of IL-6 and its receptor on stimulated monocytes. 1993 Transplant. Proc. pmid:7685949
Jonas S et al. Corticosteroid-free therapy after tacrolimus-based dual immunosuppression versus cyclosporine-based quadruple-induction therapy. 2001 Transplant. Proc. pmid:11377511
Boucher A et al. Impact of immunosuppressive regimen on cardiovascular risk factors in kidney transplant recipients. 2002 Transplant. Proc. pmid:12176582
Jiang H et al. IL-10: a tacrolimus-specific cytotoxic mediator in ongoing allograft rejection. 2001 Feb-Mar Transplant. Proc. pmid:11266931
Cirocco RE et al. Kidney recipient CMV incidence in the gancyclovir era: monitoring viral DNA by a CMV-PCR assay. 1999 Feb-Mar Transplant. Proc. pmid:10083604
Levy GA Neoral is superior to FK 506 in liver transplantation. 1998 Transplant. Proc. pmid:9723293
Shi Y et al. Comparison of Mizoribine and Mycophenolate Mofetil With a Tacrolimus-Based Immunosuppressive Regimen in Living-Donor Kidney Transplantation Recipients: A Retrospective Study in China. Transplant. Proc. pmid:28104150
Akbas SH et al. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. 2006 Transplant. Proc. pmid:16797284
First International Workshop on FK-506. A potential breakthrough in immunosuppression. Proceedings. 1987 Transplant. Proc. pmid:2445066
Gotoh M et al. Tolerance induction by liver grafting and FK 506 treatment in nonhuman primates. 1991 Transplant. Proc. pmid:1721431
Ishikawa M et al. Acetaminophen absorption test as a useful indicator of small intestinal rejection in rats. 1996 Transplant. Proc. pmid:8658911
Sindhi R et al. Preliminary immunosuppression withdrawal strategies with sirolimus in children with liver transplants. 2002 Transplant. Proc. pmid:12176651
Mühlbacher F Tacrolimus versus cyclosporin microemulsion in liver transplantation: results of a 3-month study. 2001 Feb-Mar Transplant. Proc. pmid:11267317
Fukuoka N et al. Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation. 2010 Transplant. Proc. pmid:20832577
Morales E et al. Conversion from cyclosporine to FK 506 as rescue therapy in renal transplantation with poorly steroid-responsive acute rejection. 1999 Transplant. Proc. pmid:10500562
Nardo B et al. Evidence of microchimerism after pretransplant blood transfusion and FK 506 in liver xenograft. 2000 Transplant. Proc. pmid:11134771
Miyata Y et al. Development of xenogeneic microchimerism correlated with graft outcome in hamster-to-rat heart xenotransplantation. 1998 Transplant. Proc. pmid:9723548
Alvarez-Elías AC et al. CYP3A5 Genotype and Time to Reach Tacrolimus Therapeutic Levels in Renal Transplant Children. 2016 Transplant. Proc. pmid:27110018
McManus BM et al. Impact of FK 506 on myocarditis in the enteroviral murine model. 1991 Transplant. Proc. pmid:1721463
Barten MJ et al. Assessment of immunosuppression by lymphocyte functions in human blood. 2002 Transplant. Proc. pmid:12431640
Reimer J et al. Quality of life after kidney transplantation--the impact of tacrolimus. 2001 Feb-Mar Transplant. Proc. pmid:11267573
Fritsche L et al. Conversion to mycophenolate mofetil for chronic progressive deterioration of renal allograft function: first clinical experiences in 44 patients. 1998 Transplant. Proc. pmid:9636481